Literature DB >> 1900640

Cystic fibrosis: infection.

N Høiby1.   

Abstract

Recurrent and chronic pulmonary infection is still the major cause of morbidity and mortality in cystic fibrosis. Although respiratory viruses are responsible for some of the acute exacerbations of the pulmonary disease, bacteria, and in some patients Aspergillus fumigatus, are the most important pathogens. Staphylococcus aureus and Haemophilus influenzae are the most prevalent pathogens in cystic fibrosis of childhood, whereas Pseudomonas aeruginosa and in some centres also Pseudomonas cepacia predominate in older children and adult patients. The chronic Pseudomonas aeruginosa infection is peculiar, since it is predominantly an endobronchial infection in small bronchioles caused by mucoid, alginate producing strains which gradually lose most of the O-antigenic determinants of the lipopolysaccharide. Although P. aeruginosa produces a number of other toxins which may play a role initially, most if not all of the pathology is caused by immune complex mediated chronic inflammation. The bacteriological results of antipseudomonas chemotherapy are disappointing, as these bacteria are virtually never permanently eliminated. The clinical results of repeated maintenance chemotherapy every 3 months are, however, good, since it is possible to preserve lung function for years and keep the patients alive. Antiinflammatory treatment with steroids for years is used in some patients with benefit.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1900640

Source DB:  PubMed          Journal:  Schweiz Med Wochenschr        ISSN: 0036-7672


  6 in total

1.  Cystic fibrosis and guidelines to assess significance of new colonisers?

Authors:  L Garske; J E Moore; M J Crowe; J S Elborn
Journal:  Ir J Med Sci       Date:  2002 Apr-Jun       Impact factor: 1.568

2.  Precipitating Pseudomonas aeruginosa antibodies and antimicrobial therapy in cystic fibrosis patients.

Authors:  M Trancassini; D de Vito; G Cimino; M Antonelli; S Quattrucci; P Cipriani
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-04       Impact factor: 3.267

3.  Occurrence of Burkholderia cepacia in the hospital environment.

Authors:  J E Moore; B McIlhatton; J Buchanan; D Gilpin; A Shaw; V Hall; P G Murphy; J S Elborn
Journal:  Ir J Med Sci       Date:  2002 Jul-Sep       Impact factor: 1.568

4.  Role of Pseudomonas aeruginosa lipase in inflammatory mediator release from human inflammatory effector cells (platelets, granulocytes, and monocytes.

Authors:  B König; K E Jaeger; A E Sage; M L Vasil; W König
Journal:  Infect Immun       Date:  1996-08       Impact factor: 3.441

Review 5.  Prospects for the prevention and control of pseudomonal infection in children with cystic fibrosis.

Authors:  N Høiby
Journal:  Paediatr Drugs       Date:  2000 Nov-Dec       Impact factor: 3.022

6.  Effects of mucoid and non-mucoid Pseudomonas aeruginosa isolates from cystic fibrosis patients on inflammatory mediator release from human polymorphonuclear granulocytes and rat mast cells.

Authors:  P Friedl; B König; W König
Journal:  Immunology       Date:  1992-05       Impact factor: 7.397

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.